Drug Delivery Technology enhances penetration through the mucus barrier using 2 proprietary attributes1:
AMPPLIFY® delivered more LE to target ocular tissues vs Lotemax® Suspension5
*Data from an in vivo preclinical study in 36 male rabbits, aged 6 months. Animals were randomized to receive either loteprednol etabonate 1% with AMPPLIFY® Drug Delivery Technology or Lotemax ®Suspension. Concentrations of study drugs in the aqueous humor and cornea were assayed at 5 minutes, 15 minutes, 30 minutes, 1.0, 3.0, and 6.0 hours postdosing. Clinical significance of this preclinical data has not been established.
(vs vehicle) with no concurrent NSAID use (P<0.01)*
ZERO Inflammation in 50% of patients
by Day 15
Complete resolution of inflammation (anterior chamber cell count=0), INVELTYS vs vehicle:(93/386)(51/385)
ZERO Pain in nearly 70% of patients
by Day 15
Complete resolution of pain (grade=0), INVELTYS vs vehicle:(164/386)(96/385)
LOW Incidence of significant intraocular
pressure (IOP) elevations5
Incidence of significant IOP elevations (≥10 mm Hg increase from baseline with a total measurement of ≥21 mm Hg), INVELTYS vs vehicle:(2/386)(0/385) If INVELTYS
is used for
10 days or longer,
IOP should be
*Clinical efficacy and safety were evaluated in 2 multicentered, randomized, double-masked, placebo-controlled trials in which patients with an anterior cell grade ≥2 (ie, a cell count of 6 or higher using a slit-lamp biomicroscope) after cataract surgery were assigned to INVELTYS (n=386; Study 1, n=125; Study 2, n=261) or placebo (vehicle) (n=385; Study 1, n=126; Study 2, n=259) following surgery. One to 2 drops of INVELTYS or vehicle were self-administered twice a day for 14 days beginning the day after surgery. Complete resolution of inflammation (a cell count of 0) and complete resolution of pain (a patient-reported pain grade of 0 [rated via the Subject-Rated Ocular Pain Assessment, 0=none to 5=severe]) were assessed 4, 8, and 15 days postsurgery. Consolidated clinical trial results provided above.
- Shake bottle for 1 to 2 seconds before using
- Instill 1 to 2 drops into the affected eye twice daily, beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period
- Contact lenses should be removed prior to instillation of INVELTYS and may be reinserted after 15 minutes following administration
BID STRONG with...a Commitment to patient Access
For eligible patients whose prescriptions for INVELTYS are covered by commercial insurance, use of the co-pay card may reduce co-payment responsibility to AS LITTLE AS $40
For eligible patients whose prescriptions for INVELTYS are not covered by either commercial or government insurance, use of the co-pay card may reduce co-payment responsibility to AS LITTLE AS $60
Restrictions and conditions apply.